139 related articles for article (PubMed ID: 10208638)
1. Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants.
Cravchik A; Sibley DR; Gejman PV
Pharmacogenetics; 1999 Feb; 9(1):17-23. PubMed ID: 10208638
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation.
Wilson J; Lin H; Fu D; Javitch JA; Strange PG
J Neurochem; 2001 Apr; 77(2):493-504. PubMed ID: 11299312
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of the human D2 dopamine receptor missense variants.
Cravchik A; Sibley DR; Gejman PV
J Biol Chem; 1996 Oct; 271(42):26013-7. PubMed ID: 8824240
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma S binding via human D2short and D2long dopamine receptors expressed in recombinant cells.
Gardner B; Hall DA; Strange PG
Br J Pharmacol; 1996 Jul; 118(6):1544-50. PubMed ID: 8832084
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.
Burris KD; Molski TF; Xu C; Ryan E; Tottori K; Kikuchi T; Yocca FD; Molinoff PB
J Pharmacol Exp Ther; 2002 Jul; 302(1):381-9. PubMed ID: 12065741
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action.
Wilson JM; Sanyal S; Van Tol HH
Eur J Pharmacol; 1998 Jun; 351(3):273-86. PubMed ID: 9721018
[TBL] [Abstract][Full Text] [Related]
7. The human dopamine D2(Longer) receptor has a high-affinity state and inhibits adenylyl cyclase.
Liu IS; George SR; Seeman P
Brain Res Mol Brain Res; 2000 May; 77(2):281-4. PubMed ID: 10837924
[TBL] [Abstract][Full Text] [Related]
8. The fast-off hypothesis revisited: A functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor.
Sahlholm K; Zeberg H; Nilsson J; Ögren SO; Fuxe K; Århem P
Eur Neuropsychopharmacol; 2016 Mar; 26(3):467-76. PubMed ID: 26811292
[TBL] [Abstract][Full Text] [Related]
9. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
[TBL] [Abstract][Full Text] [Related]
10. Effects of recent and reference antipsychotic agents at human dopamine D2 and D3 receptor signaling in Chinese hamster ovary cells.
Vanhauwe JF; Ercken M; van de Wiel D; Jurzak M; Leysen JE
Psychopharmacology (Berl); 2000 Jul; 150(4):383-90. PubMed ID: 10958079
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants in dopamine receptors influence on heterodimerization in the context of antipsychotic drug action.
Faron-Górecka A; Kuśmider M; Solich J; Górecki A; Dziedzicka-Wasylewska M
Prog Mol Biol Transl Sci; 2020; 169():279-296. PubMed ID: 31952689
[TBL] [Abstract][Full Text] [Related]
12. Antimanic potency of typical neuroleptic drugs and affinity for dopamine D2 and serotonin 5-HT2A receptors--a new analysis of data from the archives and implications for improved antimanic treatments.
Harrison-Read PE
J Psychopharmacol; 2009 Nov; 23(8):899-907. PubMed ID: 18635692
[TBL] [Abstract][Full Text] [Related]
13. Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors.
Chio CL; Lajiness ME; Huff RM
Mol Pharmacol; 1994 Jan; 45(1):51-60. PubMed ID: 8302280
[TBL] [Abstract][Full Text] [Related]
14. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
Perachon S; Schwartz JC; Sokoloff P
Eur J Pharmacol; 1999 Feb; 366(2-3):293-300. PubMed ID: 10082211
[TBL] [Abstract][Full Text] [Related]
15. Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors.
Hall DA; Strange PG
Br J Pharmacol; 1997 Jun; 121(4):731-6. PubMed ID: 9208141
[TBL] [Abstract][Full Text] [Related]
16. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
[TBL] [Abstract][Full Text] [Related]
17. New dopamine receptor, D2(Longer), with unique TG splice site, in human brain.
Seeman P; Nam D; Ulpian C; Liu IS; Tallerico T
Brain Res Mol Brain Res; 2000 Mar; 76(1):132-41. PubMed ID: 10719223
[TBL] [Abstract][Full Text] [Related]
18. Functional coupling of human D2, D3, and D4 dopamine receptors in HEK293 cells.
McAllister G; Knowles MR; Ward-Booth SM; Sinclair HA; Patel S; Marwood R; Emms F; Patel S; Smith A; Seabrook GR
J Recept Signal Transduct Res; 1995; 15(1-4):267-81. PubMed ID: 8903944
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D2 receptor imaging and neuroleptic drug response.
Heinz A; Knable MB; Weinberger DR
J Clin Psychiatry; 1996; 57 Suppl 11():84-8; discussion 89-93. PubMed ID: 8941175
[TBL] [Abstract][Full Text] [Related]
20. Coupling of D2 and D3 dopamine receptors to G-proteins.
Castro SW; Strange PG
FEBS Lett; 1993 Jan; 315(3):223-6. PubMed ID: 8422910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
